In the featured article from the February 2017 issue of The Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent—a PET radiotracer—is both safe and effective.
The new agent is a gallium-68 (Ga-68)-labeled peptide BBN-RGD agent that targets both gastrin-releasing peptide receptor (GRPR) and integrin ?v?3. Dual-receptor targeting provides advantages over single-receptor targeting by allowing tumor contrast when either or both receptor types are expressed, improving binding affinity and increasing the number of effective receptors.
Approximately one in seven men will be diagnosed with prostate cancer in his lifetime. In 2017, the American Cancer Society estimates that there will be more than 161,000 new prostate cancer cases in the United States and around 27,000 deaths from the disease. “Although treatable at the early stage, prostate cancer is prone to metastasis,” explain the team of authors, led by Xiaoyuan Chen, senior investigator, Laboratory of Molecular Imaging and Nanomedicine at the U.S. National Institute of Biomedical Imaging and Bioengineering. “An effective and specific imaging method of detecting both primary and metastatic lesions is thus of critical importance to manage patients with prostate cancer.”
This study included 13 patients with prostate cancer (four newly diagnosed and nine post-therapy) and five healthy volunteers. Ga-68-BBN-RGD PET/CT detected 20 bone lesions in seven patients either with primary prostate cancer or after radical prostatectomy. The patients with bone metastases did not necessarily have an elevated prostate specific antigen level. “This result is better than bone scanning with MDP,” Chen notes, referring to the most common radiotracer used today. “MDP bone scans are sensitive but lack specificity because localized skeletal accumulation of Tc-99m-MDP can also be observed in the case of trauma and infection.” No adverse side effects were found during the whole procedure and two-week follow-up, demonstrating the safety of Ga-68-BBN-RGD.
“Compounds capable of targeting more than one biomarker have the ability of binding to both early and metastatic stages of prostate cancer, creating the possibility for a more prompt and accurate diagnostic profile for both primary and the metastatic tumors,” explains Chen.
Looking ahead, Chen says, “Ga-68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.” He points out that larger-scale clinical investigations are warranted.
Receive an email update when we add a new PROSTATE CANCER article.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Myovant's Stock Soars After Relugolix Aces Late-Stage Study For Prostate Canceron November 19, 2019 at 7:59 pm
What Myovant Said About Relugolix Myovant said the Phase 3 study dubbed HERO that evaluated once-daily oral relugolix 120mg in men with advanced prostate cancer met the primary efficacy endpoint, as ...
- Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate canceron November 19, 2019 at 7:40 pm
Germline variants in androgen metabolism genes may influence clinical response to androgen deprivation therapy (ADT) in advanced prostate cancer. We sought to investigate the prognostic significance ...
- Hormone Refractory Prostate Cancer (HRPCA) Market To Reach USD 15.64 Billion By 2026| Reports And Dataon November 19, 2019 at 5:50 pm
New york, Nov. 19, 2019 (GLOBE NEWSWIRE) -- The global hormone refractory prostate cancer (HRPCA) market is forecast to reach USD 15.64 Billion by 2026, according to a new report by Reports and Data.
- With prostate cancer trial done, Peninsula drug maker will ask for FDA approval early next yearon November 19, 2019 at 12:33 pm
A Peninsula company that didn’t exist four years ago is on the cusp of asking regulators early next year to approve versions of its marquee drug against a debilitating condition in women as well as a ...
- Prostate cancer patients receiving care at MultiD clinic more likely to be advised about treatment choiceson November 19, 2019 at 9:46 am
Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of ...
- A computer model has learned to detect prostate canceron November 19, 2019 at 4:19 am
artificial intelligence not only detects the presence of cancer cells, but also evaluates the tumor according to the Gleason score, which is traditionally used in the diagnosis of prostate cancer ...
- Sleeping Habits May Increase Your Risk Of Developing The Deadly Prostate Canceron November 19, 2019 at 3:40 am
The most common form of cancer that afflicts men in the UK is prostate cancer. Since no cure has been found yet, it is vital you know the risks associated with the development of the disease. Several ...
- Why Hasn’t Immunotherapy Been Working For Prostate Cancer? Bone Tumors May Be The Answeron November 18, 2019 at 4:00 pm
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- A NF-ĸB-Activin A signaling axis enhances prostate cancer metastasison November 18, 2019 at 5:26 am
Metastasis is a main cause of death in prostate cancer (PCa). To dissect the molecular cues from cancer cell–microenvironment interaction that drive metastatic cascade, bone metastatic PCa cells were ...
via Bing News